Human Papillomavirus Infection in Relation to Vaginal Microflora and Immune Factors

  • Xiaoge Li The First Affiliated Hospital of Chongqing Medical University
  • Yutong Wu The First Affiliated Hospital of Chongqing Medical University
  • Sijing Li The First Affiliated Hospital of Chongqing Medical University
  • Xiaoling Huang The First Affiliated Hospital of Chongqing Medical University
  • Ying Jia The First Affiliated Hospital of Chongqing Medical University
DOI: https://doi.org/10.18686/aem.v12i2.362
Keywords:  HPV, Vaginal Microflora, Immune Factors, Cervical Cancer

Abstract

Objective: Clarify the vaginal microflora and immune factors in women with human papilloma virus (HPV) infection, and explore its association with HPV infection. Methods: This study collected vaginal secretions and blood from 160 women initially diagnosed as HPV positive in our hospital from June 2020 to December 2020 and 80 healthy women with HPV negative physical examination in the same period. The vaginal microflora of the patients were detected by 16S rDNA sequencing and the expression of immune factors was measured by a high-performance liquid phase chip. Results: The different types of HPV were HPV mix (64,40%), HPV52 (39,24.375%), HPV16 (30,18.750%), HPV58 (18,11.250%), HPV18 (6,3.750%), HPV53 (1,0.625%), HPV55 (1,0.625%), and HPV68 (1,0.625%).α diversity analysis showed that there was no significant difference in vaginal microflora between different HPV types (P=0.733). The genus level abundance of vaginal microflora in each group was mainly Lactobacillus, followed by Gardnerella and Prevotella. LEfSe Analysis showed that the mix group was Gardnerella and the type HPV16 group was Streptococcus. The immune comparison showed that MIP-1β was significantly upregulated in the HPV-positive group, but EGF in the HPV-negative group. Conclusion: This study revealed that HPV infection can change the proportion of vaginal microbial bacteria and the expression of immune factors, which provides a basis for local vaginal treatment and prevention of HPV infection after HPV infection.

References

[1] Chen XJ, et al. “Telomere length in cervical exfoliated cells, interaction with HPV genotype, and cervical cancer occurrence among high-risk HPV-positive women.” Cancer medicine vol. 8,10 (2019): 4845-4851.

[2] Bhattacharjee, Rahul et al. “Mechanistic role of HPV-associated early proteins in cervical cancer: Molecular pathways and targeted therapeutic strategies.” Critical reviews in oncology/hematology vol. 174 (2022): 103675.

[3] Martin DH. “The microbiota of the vagina and its influence on women's health and disease.” The American journal of the medical sciences vol. 343,1 (2012): 2-9.

[4] Mitra, Anita et al. “The vaginal microbiota, human papillomavirus infection and cervical intraepithelial neoplasia: what do we know and where are we going next?.” Microbiome vol. 4,1 58. 1 Nov. 2016.

[5] O'Hanlon, Deirdre Elizabeth et al. “Vaginal pH measured in vivo: lactobacilli determine pH and lactic acid concentration.” BMC microbiology vol. 19,1 13. 14 Jan. 2019.

[6] Ilhan, Zehra Esra et al. “Deciphering the complex interplay between microbiota, HPV, inflammation and cancer through cervicovaginal metabolic profiling.” EBioMedicine vol. 44 (2019): 675-690.

[7] Chorna, Nataliya et al. “Cervicovaginal Microbiome and Urine Metabolome Paired Analysis Reveals Niche Partitioning of the Microbiota in Patients with Human Papilloma Virus Infections.” Metabolites vol. 10,1 36. 15 Jan. 2020.

[8] Torres-Poveda, K et al. “A prospective cohort study to evaluate immunosuppressive cytokines as predictors of viral persistence and progression to pre-malignant lesion in the cervix in women infected with HR-HPV: study protocol.” BMC infectious diseases vol. 18,1 582. 19 Nov. 2018.

[9] Dunlop AL, et al. “Maternal Microbiome and Pregnancy Outcomes That Impact Infant Health: A Review.” Advances in neonatal care : official journal of the National Association of Neonatal Nurses vol. 15,6 (2015): 377-85.

[10] Cao B et al. “Placental Microbiome and Its Role in Preterm Birth.” NeoReviews vol. 15,12 (2014): e537-e545.

[12] Zhang S, Zhao F. Comment on "Will HPV vaccination prevent cervical cancer"[J]. BMC Medicine, 2020, 18(1):38-41.

[13] Song F, Du H, Wang C, et al. The effectiveness of HPV16 and HPV18 genotyping and cytology with different thresholds for the triage of human papillomavirus-based screening on self-collected samples[J]. PLoS ONE, 2020, 15(6):518-522.

[14] Huh WK, Ault KA, Chelmow D, Davey DD, Goulart R A, Garcia F A R, et al. Use of Primary High-Risk Human Papillomavirus Testing for Cervical Cancer Screening: Interim Clinical Guidance. Gynecol. Oncol. 2015, 136 (2), 178–182.
Published
2023-06-01
Issue
Vol 12, No 2 (2023)
Section
Original Research Article

Copyright (c) 2023 Xiaoge Li

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors submitting to USP journals agree to publish their manuscript under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) where authors agree to allow third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear

Authors retain copyright of their work, with first publication rights (online and print) granted to Universe Scientific Publishing or the owner of the journal in question.